Hikma’s US Biosimilars Ambitions Begin With $150m Ustekinumab Deal

Firm Signs Commercialization and License Agreement With Bio-Thera Solutions

 
• By Dean Rudge
  
Generate a summary of this article
Listen to this article
Beta

Hikma told Generics Bulletin earlier this year it was reevaluating the US biosimilars market after witnessing successful launches from several of its rivals. Now the London-based firm has signed an agreement in the US to license and commercialize Bio-Thera Solutions’ Stelara biosimilar candidate.

Deals Sign
Hikma has signed a US deal, following several in the MENA region • Source: Alamy

Hikma Pharmaceuticals plc reiterated its ambitions to tap into the “growth of the biosimilar market in the US” as it announced an agreement worth up to $150m to in-license Bio-Thera Solutions’ BAT2206 biosimilar ustekinumab candidate, with the race to compete with Johnson & Johnson’s Stelara autoimmune disorders blockbuster continuing to heat up.

Under terms of the agreement, Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206, which is currently undergoing...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.